Category: Joint ventures/collaborations
-
Partnership to Study Biomarkers in Liquid Biopsies
6 October 2015. DeNovo Sciences, a developer of liquid biopsies and analytics, is teaming with bioTheranostics, a cancer diagnostics company using molecular biomarkers, to test the feasibility of combining their technologies. Financial and intellectual property details of the collaboration were not disclosed. In testing for solid tumor cancers, such as lung or breast cancer, doctors…
-
Nanotech Cancer Center Gains $10.1M Funding
1 October 2015. Cornell University and Memorial Sloan Kettering Cancer Center are developing cancer diagnostics and therapies with nanoscale particles, funded largely by a National Cancer Institute grant. NCI, part of National Institutes of Health, is providing $8.2 million to the institutions over five years, while Sloan Kettering is adding $1.9 million. Cornell and Sloan…
-
NASA to Test Hand-Held DNA Sequencer in Space Station
30 September 2015. Astronauts aboard the International Space Station will take part in experiments testing the feasibility of a portable DNA sequencing device in space. The proof-of-concept test of the hand-held MinIon DNA sequencing device is a project of National Aeronautics and Space Administration. The MinIon, made by Oxford Nanopore Technologies in the U.K., is…
-
Sensor Network, Google Maps to Track California Air Quality
28 September 2015. A San Francisco company that designs environmental sensors and networks is partnering with Google Maps to track air quality in three California regions. Aclima Inc. and Google Maps announced the partnership today at the annual meeting of the Clinton Global Initiative in New York, but no financial details were revealed. Aclima Inc. develops…
-
Spin-Off Formed to Develop Brain Disorder Therapies
16 September 2015. A new enterprise developing biologic therapies for disorders of the brain and nervous system is underway, spun-off from the acquisition in July 2015 of Naurex Inc. by the pharmaceutical company Allergan plc. The new company, Aptinyx Inc. in Evanston, Illinois will have many of the same team at Naurex, itself a spin-off enterprise from Northwestern…
-
Celgene, Antibody Network Partner on Cancer Targets
15 September 2015. The biopharmaceutical company Celgene Corp. is collaborating with a consortium of university protein engineering labs to identify targets for antibodies that harness the immune system to treat cancer. The deal provides Celgene with an option to license antibody candidates addressing cancer targets from the consortium, known as Recombinant Antibody Network, for which…
-
NIH Backing Alzheimer’s Onset Drug Trial
15 September 2015. National Institute on Aging, part of National Institutes of Health, is funding a late-stage clinical trial testing a current epilepsy drug as a treatment to delay the early onset of Alzheimer’s symptoms. The $7.5 million grant, part of NIH’s national plan to address Alzheimer’s disease, supports the trial testing a low-dose formulation…
-
Seattle Children’s, Biotech Collaborate on Gene Editing
11 September 2015. The biotechnology company bluebird bio and Seattle Children’s Research Institute are partnering on gene editing technologies to treat inherited pediatric diseases. Their agreement calls for bluebird bio — the name is spelled in all lower-case characters — based in Cambridge, Massachusetts and Seattle — to provide $3 million for research on these…
-
Research Group, CureVac Partner on AIDS Vaccine
10 September 2015. An organization encouraging development of AIDS vaccines and the pharmaceutical company CureVac are collaborating on creating a potent AIDS vaccine technology. Financial and intellectual property aspects of the partnership between the not-for-profit International AIDS Vaccine Initiative, or IAVI, and CureVac in Tubingen, Germany were not disclosed. IAVI sponsors research and development of…
-
Alliance Mounts Comprehensive ALS Research Program
9 September 2015. A coalition of three medical centers in the U.S. is leading a comprehensive research initiative to find treatments and eventually cures for amyotrophic lateral sclerosis, or ALS. The collaboration, known as Answer ALS brings together researchers from Johns Hopkins University in Baltimore, Cedars-Sinai Medical Center in Los Angeles, and Massachusetts General Hospital…